This is the final installment of three parts in the same question. Two previous installments are; link: https://piotrpeterblog.com/2021/08/09/cassava-science-results-vs-anavex-life-sciences-projections-sava-avxl/ link: https://piotrpeterblog.com/2021/09/27/why-sava-simufilam-might-not-have-any-advantage-over-avxl-blarcamesine-sava-avxl-crtx-snpx/ The Proper Mix If we are to assess the chances of Blarcamesnie to better its results in Alzheimer's phase 2b/3 then first we have to list the known factors impacting the response of the patients. … Continue reading Can Blarcamesine Catch Up to Simufilam and Surpass it? $AVXL $SAVA $CTRX

So called previous post link https://piotrpeterblog.com/2021/08/09/cassava-science-results-vs-anavex-life-sciences-projections-sava-avxl/ This post is rather a continuation of that post. $SAVA, The First in The Race Contender The share price of $SAVA has taken some beating over the alegations of, let's say it outloud, fraud. Nevertheless, the price has been staging some comeback. Either, due to short memory of the … Continue reading Why $SAVA Simufilam Might Not Have Any Advantage Over $AVXL Blarcamesine $SAVA $AVXL $CRTX $SNPX